Corvus 制药 CRVS
$10.54 +$0.81 (+8.32%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $10.60 +0.57%
开盘$10.65
昨收$9.73
当日区间$9.64 – $10.96
成交量1.26M
市值$889.08M
市盈率（TTM）–
股息率–
财报
财报日平均波动±7.4%近16次财报
收涨次数9 / 1656% 的概率
最佳反应+32.2%
最差反应-14.8%
每次财报后次日股价变动
| 季度 | 财报日期 | 时段 | 隐含波动 | 实际波动 | 较隐含波动 |
|---|---|---|---|---|---|
| 2026/Q2 | 6 Aug 2026 | After Market | ±12.8% | +0.43% | 符合区间 |
| 2026/Q1 | 7 May 2026 | After Market | ±11.9% | +6.58% | 符合区间 |
| 2025/Q4 | 12 Mar 2026 | After Market | ±12.3% | -4.31% | 符合区间 |
| 2025/Q3 | 4 Nov 2025 | After Market | ±18.4% | -1.44% | 符合区间 |
| 2025/Q2 | 7 Aug 2025 | After Market | ±19.9% | +4.36% | 符合区间 |
| 2025/Q1 | 8 May 2025 | After Market | ±43.5% | +32.24% | 符合区间 |
| 2024/Q4 | 25 Mar 2025 | After Market | ±37.7% | -14.76% | 符合区间 |
| 2024/Q3 | 12 Nov 2024 | After Market | ±24.9% | +2.07% | 符合区间 |
| 2024/Q2 | 6 Aug 2024 | After Market | ±20.3% | +9.67% | 符合区间 |
| 2024/Q1 | 6 May 2024 | After Market | ±28.8% | -12.04% | 符合区间 |
| 2023/Q4 | 19 Mar 2024 | After Market | ±44.1% | -5.61% | 符合区间 |
| 2023/Q3 | 7 Nov 2023 | None | ±28.5% | +1.27% | 符合区间 |
| 2023/Q2 | 8 Aug 2023 | None | ±15.4% | +7.94% | 符合区间 |
| 2023/Q1 | 8 May 2023 | None | ±29.2% | -0.38% | 符合区间 |
| 2022/Q4 | 28 Mar 2023 | After Market | ±46.3% | +11.34% | 符合区间 |
| 2022/Q3 | 3 Nov 2022 | After Market | ±28.9% | -3.36% | 符合区间 |
"隐含波动"指财报发布前期权市场定价的预期波幅。"波动"指财报发布后首个交易日的股价变化。
基本面
最新报告季度：Q2, ended Jun 2026
营收$0.00
营业利润-$19.30M-88.1% YoY
净利润-$17.96M-124.5% YoY
摊薄每股收益-$0.19-90.0% YoY
自由现金流-$15.98M-171.3% YoY
经营现金流-$15.40M
营收，近8个季度
净利润，近8个季度
盈利能力与资产负债表
净资产收益率-35.4%
资产收益率-32.9%
投入资本回报率-38.6%
流动比率16.16
负债/资产比率5.8%
现金及投资$215.23M
总负债$274,000.00
净现金（净负债）$214.95M
暂无评论——快来第一个聊聊 CRVS。
登录后参与讨论。